Content Shortcuts
회사소개페이지 비주얼이미지입니다.
About Us

We always consider new possibilities and
prepare for the future

Overview
KOLON Life Science will continue to pursue its dream of stepping up to become a specialized Global
Leading Cell & Gene Therapy company in the future. It seeks to do this by promoting the development of
its biopharmaceutical business based on the growth and profitability of its fine chemical businesses
including active pharmaceutical ingredients (API), specialty chemicals and water solution.

In particular, KOLON Life Science has developed for the first time in the world a new medicine in the form of cell and gene treatment for degenerative
arthritis from which many people suffer in this era of aging populations. In addition, KOLON Life Science is also concentrating its research capacity in
the field of gene medicine including neuropathic pain medicine and anti-cancer drugs. KOLON Life Science will continue to promote its substantial
growth through market expansion for its fields of business, alliance with global partners and the development of new products.

Date of establishment
April 21, 2000
CEO
SUN JIN KIM
MD, PhD
Number of employees
463 employees
(as of March 2023)
Listing
KOSDAQ (102940)
History
  1. 2005
    1. 12
      Take over of active pharmaceutical ingredients and eco-friendly materials business from KOLON
    2. 09
      Filing of application for KFDA IND of 'TissueGene-C'
    3. 08
      Selection of ‘Degenerative arthritis treatment TissueGene-C commercialization’ as Ministry of Commerce, Industry, and Energy’s biostar project
    4. 06
      Filing of application for U.S. FDA IND of 'TissueGene-C'
    5. 04
      Success in commercialization of new development -Voglibose (diabetes medicine)
  2. 2004
    1. 04
      Success in commercialization of new development - KP-324 (eco-friendly flame retardant), 5-FC (intermediate ingredient of AIDS medicine)
  3. 2003
    1. 04
      Success in commercialization of medicine and pharmaceutical ingredient-Nadifloxacin (antibiotic) and Zaltoprofen (anti-inflammatory drug)
  4. 2002
    1. 11
      Conclusion of contract for distribution of KP-1465(antioxidant) to 'Shiba Special Chemical'
    2. 07
      Selection of 'TissueGene-C' as Ministry of Commerce, Industry, and Energy’s health & medical technology promotion project (Commercialization of Tissuegene-C or development of its analogue for the treatment of generative arthritis using cell-mediated gene therapy)
    3. 06
      Conclusion of contract for distribution of cephalosporin intermediates to ‘GSK’
    4. 04
      Conclusion of contract for distribution of CleanBio to ‘Unilever’
    5. 04
      Success in commercialization of medicine and pharmaceutical ingredient – Felbinac(anti-inflammatory), Levofloxacin(antibiotic)
  5. 2001
    1. 12
      Acquisition of BGMP certificate for Incheon plant
  6. 2000
    1. 04
      Establishment of Korea TissueGene Asia, Ltd.
  1. 2007
    1. 12
      Conclusion of contract to adopt global new medicine candidate material technology for anti-influenza
    2. 03
      Acquisition of ISO 9001 certification for Kimchun plant
    3. 01
      Conclusion of contract to adopt Genexine’s new bio medicine, p40-hFc(autoimmune disease drug)
    4. 01
      Acquisition of IRB approval for 'TissueGene-C' from Korea Clinical Research Organization
  2. 2006
    1. 12
      Acquisition of approval for Clinical Phase I of 'TissueGene-C'; Korea KFDA, acquisition of IRB approval for ‘TissueGene-C’ from U.S. Clinical Research Organization
    2. 07
      Acquisition of approval for Clinical Phase I of 'TissueGene-C'; U.S. FDA
    3. 04
      uccess in commercialization of newly developed-Argatroban(anticoagulant)
    4. 03
      Acquisition of ISO 9001/ISO 14001, OHSAS 18001 for Incheon plant’s lab
    5. 01
      Take over of active pharmaceutical ingredients and eco-friendly material business from KOLON Chemical Co. change of name to KOLON Life Science
  1. 2022
    1. 04
      TG-C License-out Agreement signed with Juniper Biologics
  2. 2020
    1. 12
      Bio manufacturing division split-off,
      KOLON BIOTECH established
    2. 02
      Designation of KLS-2031 as US FDA Fast Track
  3. 2019
    1. 05
      Completion of the 2nd plant for Invossa
    2. 03
      Acquisition of approval for IND of KLS-2031 (treatment for neuropathic pain)
  4. 2018
    1. 11
      Began the phase 3 clinical test for Invossa in the U.S.
    2. 04
      Relocated the main office and the research institute (Magok, Seoul)
  5. 2017
    1. 11
      Approved the phase 3 clinical test plan for adding the indication of a mild case with Invossa®-K Inj.
    2. 11
      Launched Invossa®-K Inj. 
    3. 07
      Acquired the domestic item approval for Invossa®-K Inj. 
  6. 2016
    1. 07
      Applied for domestic sales approval of Invossa®-K Inj. to Ministry of Food and Drug Safety
    2. 04
      Completed the phase 3 clinical test for Invossa®-K Inj.
  7. 2015
    1. 06
      Finalized the brand name of Invossa ('TissueGene-C')
    2. 05
      Acquisition of approval for Clinical Phase III of ‘TissueGene-C’ (USFDA)
  8. 2014
    1. 06
      Completion of new Biopharmaceutical plant (Chungju)
    2. 04
      Conclusion of MOU with University of California, San Diego for R&D cooperation
  9. 2013
    1. 08
      Acquisition of approval for Clinical Phase III of 'TissueGene-C' (KFDA)
  10. 2012
    1. 10
      Completion of new active pharmaceutical ingredients cGMP plant (Chungju)
    2. 03
      Change of CEO(CEO, Woo-Suk Lee)
    3. 02
      Change of headquarter location ((Byulyang-dong) 13, KOLONro, Gwachun-si, Kyunggi-do)
  11. 2011
    1. 04
      Completion of new antimicrobial and water treatment agent plant (Kimchun)
  12. 2010
    1. 12
      Acquisition of approval for Clinical Phase IIb of 'TissueGene-C'
    2. 11
      Procurement of site for new plant in Chungju Company City
    3. 07
      Change of largest shareholder to KOLON Corporation (Included into holding company as a subsidiary company)
    4. 07
      Decision made to construct new antimicrobial and water treatment agent plant
  13. 2009
    1. 05
      Completion of active pharmaceutical ingredients cGMP plant within Eumseong factory
    2. 04
      Approval of screening of going public on the KOSDAQ, Korea Exchange
    3. 02
      Acquisition of approval for Clinical Phase IIa of 'TissueGene-C'; Korea KFDA
  14. 2008
    1. 10
      Approval of screening in preparation of going public on the KOSDAQ, Korea Exchange
    2. 06
      Claim for a screening in preparation of going public on the KOSDAQ, Korea Exchange
맨 위로